GSK Total Liabilities 2010-2022 | GSK

GSK total liabilities from 2010 to 2022. Total liabilities can be defined as the total value of all possible claims against the corporation.
  • GSK total liabilities for the quarter ending June 30, 2022 were $83.371B, a 7.6% increase year-over-year.
  • GSK total liabilities for 2021 were $79.427B, a 3.75% increase from 2020.
  • GSK total liabilities for 2020 were $76.556B, a 2.25% decline from 2019.
  • GSK total liabilities for 2019 were $78.319B, a 7.87% increase from 2018.
GSK Annual Total Liabilities
(Millions of US $)
2021 $79,427
2020 $76,556
2019 $78,319
2018 $72,605
2017 $68,167
2016 $73,346
2015 $68,144
2014 $58,862
2013 $53,632
2012 $55,047
2011 $51,747
2010 $49,956
2009 $51,451
GSK Quarterly Total Liabilities
(Millions of US $)
2022-06-30 $83,371
2022-03-31 $89,977
2021-12-31 $79,427
2021-09-30 $78,516
2021-06-30 $77,484
2021-03-31 $78,698
2020-12-31 $76,556
2020-09-30 $77,898
2020-06-30 $80,042
2020-03-31 $82,349
2019-12-31 $78,319
2019-09-30 $80,380
2019-06-30 $77,997
2019-03-31 $76,840
2018-12-31 $72,605
2018-09-30 $71,510
2018-06-30 $74,327
2018-03-31 $73,155
2017-12-31 $68,167
2017-09-30 $70,637
2017-06-30 $68,811
2017-03-31 $66,446
2016-09-30 $71,954
2016-06-30 $76,625
2016-03-31 $68,686
2015-12-31 $68,144
2015-09-30 $67,895
2015-06-30 $66,726
2015-03-31 $70,632
2014-12-31 $58,862
2014-09-30 $57,738
2014-06-30 $53,880
2014-03-31 $53,423
2013-12-31 $53,632
2013-09-30 $53,179
2013-06-30 $53,441
2013-03-31 $54,807
2012-12-31 $55,047
2012-09-30 $52,808
2012-06-30 $54,889
2012-03-31 $49,056
2011-12-31 $51,747
2011-09-30 $53,485
2011-06-30 $53,273
2011-03-31 $52,338
2010-12-31 $49,956
2010-09-30 $49,648
2010-06-30 $49,992
2010-03-31 $51,731
2009-12-31 $51,451
2009-09-30 $52,805
2009-06-30 $43,727
2009-03-31 $44,729
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $61.844B $46.910B
GSK plc is a biopharma company. Its vaccine portfolio protects people from meningitis, shingles, flu, polio, measles and many more. GSK plc, formerly known as GLAXOSMITHKLINE, is based in Brentford, the United Kingdom.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $152.564B 9.26
Bio-Rad Laboratories (BIO.B) United States $13.545B 29.93
QIAGEN (QGEN) Netherlands $9.898B 16.57
Ginkgo Bioworks Holdings (DNA) United States $5.908B 0.00
Myovant Sciences (MYOV) United Kingdom $2.391B 0.00
Arcus Biosciences (RCUS) United States $2.007B 39.18
Emergent Biosolutions (EBS) United States $1.039B 6.02
Biohaven Pharmaceutical Holding (BHVN) United States $0.878B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.392B 0.00
Zymeworks (ZYME) Canada $0.354B 0.00
Enzo Biochem (ENZ) United States $0.113B 0.00
Gelesis Holdings (GLS) United States $0.087B 0.00
SQZ Biotechnologies (SQZ) United States $0.075B 0.00
Ambrx Biopharma (AMAM) United States $0.045B 0.00